Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mark Jesky"'
Autor:
Mark Jesky, Paul Cockwell, Anthony Fenton, Punit Yadav, Stephen Harding, Charles J. Ferro, Rachel Webster, Indranil Dasgupta, Iain L. C. Chapple, Stephanie Stringer
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 5, p e0197043 (2018)
PLoS ONE, Vol 13, Iss 5, p e0197043 (2018)
BACKGROUND Patients with chronic kidney disease (CKD) are at an increased risk of developing end-stage renal disease (ESRD). We assessed for the first time whether urinary free light chains (FLC) are independently associated with risk of ESRD in pati
Autor:
Mark Jesky, Anthony Fenton, Peter Boor, Federica Genovese, Morten A. Karsdal, Daniel Guldager Kring Rasmussen, Martin Tepel, Paul Cockwell, Charles J. Ferro
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Rasmussen, D G K, Fenton, A, Jesky, M, Ferro, C, Boor, P, Tepel, M, Karsdal, M A, Genovese, F & Cockwell, P 2017, ' Urinary endotrophin predicts disease progression in patients with chronic kidney disease ', Scientific Reports, vol. 7, 17328 . https://doi.org/10.1038/s41598-017-17470-3
Scientific Reports
Scientific reports 7, 17328 (2017). doi:10.1038/s41598-017-17470-3
Rasmussen, D G K, Fenton, A, Jesky, M, Ferro, C, Boor, P, Tepel, M, Karsdal, M A, Genovese, F & Cockwell, P 2017, ' Urinary endotrophin predicts disease progression in patients with chronic kidney disease ', Scientific Reports, vol. 7, 17328 . https://doi.org/10.1038/s41598-017-17470-3
Scientific Reports
Scientific reports 7, 17328 (2017). doi:10.1038/s41598-017-17470-3
Scientific reports 7(1), 17328 (2017). doi:10.1038/s41598-017-17470-3
Published by Nature Publishing Group, London
Published by Nature Publishing Group, London
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce16ae8627f30458645a999659e00379
Autor:
Daniel Guldager Kring Rasmussen, Anthony Fenton, Morten A. Karsdal, Mark Jesky, Paul Cockwell, Signe Holmh Nielsen, Federica Genovese, Susanne Brix, Charles J. Ferro
Publikováno v:
Holm Nielsen, S, Guldager Kring Rasmussen, D, Brix, S, Fenton, A, Jesky, M, Ferro, C J, Karsdal, M, Genovese, F & Cockwell, P 2018, ' A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease ', PLOS ONE, vol. 13, no. 10, e0204239 . https://doi.org/10.1371/journal.pone.0204239
Nielsen, S H, Rasmussen, D G K, Brix, S, Fenton, A, Jesky, M, Ferro, C J, Karsdal, M, Genovese, F & Cockwell, P 2018, ' A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease ', PLOS ONE, vol. 13, no. 10, e0204239 . https://doi.org/10.1371/journal.pone.0204239
PLoS ONE
PLoS ONE, Vol 13, Iss 10, p e0204239 (2018)
Nielsen, S H, Rasmussen, D G K, Brix, S, Fenton, A, Jesky, M, Ferro, C J, Karsdal, M, Genovese, F & Cockwell, P 2018, ' A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease ', PLOS ONE, vol. 13, no. 10, e0204239 . https://doi.org/10.1371/journal.pone.0204239
PLoS ONE
PLoS ONE, Vol 13, Iss 10, p e0204239 (2018)
Background: Patients with chronic kidney disease (CKD) have increased risk of development of endstage renal disease (ESRD) and early mortality. Fibrosis is the central pathogenic process in CKD and is caused by dysregulated extracellular matrix (ECM)
Autor:
Charles J. Ferro, Anthony Fenton, Mark Jesky, Federica Genovese, Paul Cockwell, Jacob R. Sorensen, Morten A. Karsdal
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0175200 (2017)
PLoS ONE
PLoS ONE
Background Patients with chronic kidney disease (CKD) are at increased risk of end-stage renal disease (ESRD) and early mortality. The underlying pathophysiological processes are not entirely understood but may include dysregulation of extracellular
Autor:
Punit Yadav, Khai Ping Ng, Charles J. Ferro, Paul Cockwell, Mark Jesky, Rajbir Athwal, Mary Dutton, Stephanie Stringer
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 3, p e91961 (2014)
PLoS ONE, Vol 9, Iss 3, p e91961 (2014)
Background Arterial stiffness is increased in patients with CKD and is a powerful predictor of cardiovascular morbidity and mortality. Use of the xanthine oxidase inhibitor allopurinol has been shown to improve endothelial function, reduce left ventr